Drugs / EDP1066
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03542994 | Apr 2019 → Jan 2020 | atopic eczema, psoriasis | Evelo Biosciences, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EDP1066 | “EDP1066 is an orally administered monoclonal microbial” NCT03542994 ↗ |
| Route | Oral | “EDP1066 is an orally administered monoclonal microbial” NCT03542994 ↗ |